Table 1.
siRNA cancer therapeutics in clinical trials.
| Drug | Company | Vehicle | Target | Disease | Delivery route | Phase | Stage |
|---|---|---|---|---|---|---|---|
| CALAA-01 | Calando Pharma | Cyclodextrin nanoparticle, Transferrin, PEG | M2 subunit of ribonucleotide reductase | Solid tumors | IV | I | Ongoing, not recruiting |
|
| |||||||
| Atu027 | Silence Therapeutics | Liposomes (Lipoplexes, Cationic lipid) | Protein kinase N3 | Solid tumors | IV | I | Completed |
|
| |||||||
| ALN-VSP02 | Alnylam Pharma | SNALP | VEGF and KSP | Solid tumors with liver involvement | IV | I | Completed |
| Solid tumors | IV | I | Completed | ||||
|
| |||||||
| TKM 080301 | Tekmira Pharma | SNALP | Polo-kinase-1 | Solid tumors | IV | I | Recruiting |
| Solid tumors with liver involvement | IV | I | Completed | ||||
|
| |||||||
| siRNA-EphA2-DOPC | M.D. Anderson Cancer Center | Liposomes (neutral liposomes) | EphA2 | Solid tumors | IV | I | Not yet open |
|
| |||||||
| siG12D LODER | Silenseed Ltd | Polymer matrix (LODER polymer) | KRASG12D | Pancreatic ductal adenocarcinoma | EUS biopsy needle | I | Ongoing, recruiting |
| II | Not yet open | ||||||